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G E N E T I C S
Mre11 exonuclease activity removes the 
chain-terminating nucleoside analog gemcitabine 
from the nascent strand during DNA replication
L. Boeckemeier1*, R. Kraehenbuehl1,2*, A. Keszthelyi1†, M. U. Gasasira1†, E. G. Vernon1, 
R. Beardmore1, C. B. Vågbø3, D. Chaplin2, S. Gollins1, H. E. Krokan3, S. A. E. Lambert4,  
B. Paizs2, E. Hartsuiker1‡
The Mre11 nuclease is involved in early responses to DNA damage, often mediated by its role in DNA end processing. 
MRE11 mutations and aberrant expression are associated with carcinogenesis and cancer treatment outcomes. 
While, in recent years, progress has been made in understanding the role of Mre11 nuclease activities in DNA 
double-strand break repair, their role during replication has remained elusive. The nucleoside analog gemcitabine, 
widely used in cancer therapy, acts as a replication chain terminator; for a cell to survive treatment, gemcitabine 
needs to be removed from replicating DNA. Activities responsible for this removal have, so far, not been identi-
fied. We show that Mre11 3′ to 5′ exonuclease activity removes gemcitabine from nascent DNA during replication. 
This contributes to replication progression and gemcitabine resistance. We thus uncovered a replication-supporting 
role for Mre11 exonuclease activity, which is distinct from its previously reported detrimental role in uncontrolled 
resection in recombination-deficient cells.
INTRODUCTION
Error-free DNA replication is essential for maintaining genome 
stability and for preventing the accumulation of mutations, which 
drive carcinogenesis. Replication fork blockage interferes with cell 
division and contributes to genome instability. Different sources of 
replication stress can impede fork progression, e.g., a lack of deoxy-
nucleotide triphosphates (dNTPs), or obstacles (e.g., DNA lesions) 
in the template strand. Various mechanisms have evolved to deal 
with these sources of replication stress (1).
Homologous recombination (HR) is a well-studied mechanism 
involved in repair of DNA double-strand breaks (DSBs). In HR, the 
DNA is repaired through invasion of a broken DNA strand into a 
homologous DNA duplex followed by copy synthesis. Before strand 
invasion takes place, 5′ DSB ends are resected to create 3′ single- 
strand overhangs (2). One of the proteins responsible for end resec-
tion is Mre11, part of the Mre11/Rad50/Nbs1 (MRN) complex.
MRN is highly conserved among eukaryotes and is, together 
with CtIP, involved in a wide range of early responses to DNA dam-
age, often mediated by its role in DNA end processing (3). Central 
to DNA end processing are Mre11 single-strand endonuclease and 
3′ to 5′ exonuclease activities. The role of Mre11 exonuclease activ-
ity in HR has long been enigmatic, as the 3′ to 5′ polarity is in the 
opposite direction of the 5′ to 3′ resection required for HR. More 
recently, several studies suggest that the Mre11 endonuclease activity 
creates single-strand nicks, which serve as entry points for the 
Mre11 3′ to 5′ exonuclease activity directed toward the break, while 
other (nuclease) activities are responsible for resection away from 
the break (4–6). After resection, invasion of the 3′ end of the DSB 
into homologous DNA is mediated by Rad51, aided in humans by 
BRCA1, BRCA2, and several RAD51 paralogues. The invading 
3′ end acts as a primer for copy synthesis (2).
Several Mre11 functions are independent of its nuclease activi-
ties. Saccharomyces cerevisiae mre11 nuclease-deficient mutants are 
only partially sensitive to ionizing radiation and are proficient for 
several other phenotypes observed in mre11 null mutants (7). In 
Schizosaccharomyces pombe, resection of the C-rich strand at telo-
mere ends requires Mre11 but is independent of its nuclease activi-
ties (8), while an mre11 nuclease mutant is defective in Rec12Spo11 
removal and shows sensitivity to topoisomerase poisons but not to 
methyl methanesulfonate and ionizing radiation (9).
MRN/CtIP and other proteins involved in HR have also been 
implicated in the restart of stalled replication forks after they en-
counter an obstacle in the template strand (10–16). The precise role 
of the MRN complex, and especially the role of the Mre11 nuclease 
activity in replication fork restart, is not understood. S. cerevisiae 
Mre11 is recruited to paused replication forks and stabilizes their 
association with replisome components, but this function does not 
depend on the Mre11 nuclease activity (17). In S. pombe, enrich-
ment of the HR protein Rad52 at stalled forks is dependent on the 
MRN complex (14) but is independent of Mre11 nuclease activity 
(18). In absence of some HR proteins in human cells (e.g., when 
RAD51 or BRCA2 are mutated/depleted), MRE11 exonuclease ac-
tivity is responsible for uncontrolled deleterious degradation of stalled 
and reversed forks (19). However, it remains unknown whether and 
how MRE11 nuclease activity supports replication progression in 
recombination-proficient cells.
While DNA damage response mechanisms that deal with fork 
stalling caused by nucleotide pool depletion or obstacles on the 
template strand have been widely studied (20), less is known about 
mechanisms that deal with the replication blockage of the nascent 
strand, e.g., caused by incorporation of chain-terminating nucleo-
tides. Nucleoside analogs are frequently used in cancer therapy. 
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They interfere with DNA replication by inhibiting nucleotide me-
tabolism and can act as DNA replication chain terminators after 
incorporation into nascent DNA (21). The nucleoside analog 
gemcitabine [2′,2′-difluoro 2′-deoxycytidine (dFdC)], used to treat 
a range of cancers (22), is a deoxycytidine analog that contains two 
fluorine atoms at the 2′ carbon of the sugar ring. It is a prodrug that, 
once transported into a cell, is phosphorylated into dFdC mono-
phosphate (dFdCMP) by deoxycytidine kinase (dCK) and subse-
quently to dFdC diphosphate (dFdCDP) and dFdC triphosphate 
(dFdCTP) (22). Competing with deoxycytidine triphosphate, dFdCTP 
is incorporated into the nascent DNA strand during replication, 
which leads to chain termination after incorporation of an additional 
dNTP (23). In addition, dFdCDP acts as an inhibitor of ribonucleo-
tide reductase (RNR), depleting the dNTP pools, thus increasing 
the likelihood of dFdCTP integration (22).
Little is known about DNA repair pathways resisting treatment 
with dFdC. Chinese hamster ovary (CHO) cell nucleotide excision 
repair (xpd and ercc1), nonhomologous end joining (DNA-pkcs), 
base excision repair (xrcc1), and HR (xrcc3) mutants are not sensi-
tive to dFdC (24). In contrast, mutation of BRCA2 in CHO cells and 
small interfering RNA (siRNA) knockdown of human RAD51 in-
crease dFdC resistance (25).
For a cell to be able to resist treatment with dFdC, the chain- 
terminating nucleoside analog must be removed to allow replication 
restart. Little is known about mechanisms that remove replication- 
terminating dFdC (or other chain-terminating nucleoside analogs) 
from nascent DNA. In vitro, the proofreading exonuclease activity 
of DNA polymerase  is able to remove the chain-terminating nu-
cleoside analog cytarabine from DNA ends (23), and this activity 
contributes to cellular cytarabine tolerance (26). However, this ac-
tivity is not able to efficiently remove dFdCMP from a 3′ DNA end 
or from the penultimate (masked by another nucleotide) position 
(23). Similarly, the human-base excision repair nuclease Ape1 was 
shown to be able to remove l-configuration nucleoside analogs 
(e.g., troxacitabine) from DNA but had little activity against dFdC 
or other d-configuration nucleoside analogs (27). TDP1 is able to 
remove cytarabine from 3′ DNA ends in vitro, and TDP1−/− DT40 cells 
and mouse embryonic fibroblasts are hypersensitive to this drug, 
while they are not sensitive to dFdC (28). Hence, the identity of the 
enzyme(s) involved in dFdC removal has remained elusive.
We have previously shown that the nuclease activity of fission 
yeast Mre11 is involved in removing covalently bound Spo11 (29), 
topoisomerase I, and topoisomerase II (9) from DNA. After dFdC 
treatment, MRN proteins form nuclear foci at stalled forks in the 
absence of detectable DNA breaks, while siRNA knockdown of 
Mre11, Rad50 (30), and mirin treatment (31) causes a slight dFdC 
sensitivity in human cells. A recent study (32) in DT40 cells showed 
that some other nucleoside analogs (dFdC was not tested) retard 
replication in Mre11 nuclease mutants. However, removal of these 
nucleoside analogs from genomic DNA was not assessed, and it has 
remained unknown whether the observed phenotypes in these mu-
tants were due to a role of Mre11 in resisting nucleotide pool imbal-
ances (caused by treatment with nucleoside analogs) or whether 
Mre11 nuclease activity is involved in removal of chain-terminating 
nucleoside analogs. In addition, as the MRE11 mutants used for this 
study were defective for both endo- and exonuclease activity, it has 
remained unclear whether replication delay was caused by an endo- 
or exonuclease defect. We thus decided to test the potential roles 
for the Mre11 endo- and exonuclease activities in removing the 
chain-terminating nucleoside analog dFdC from genomic DNA 
during DNA replication in several model organisms.
RESULTS
Creation of a nucleotide salvage pathway in S. pombe
As S. pombe does not have a functional nucleotide salvage pathway 
that would allow the uptake and phosphorylation of dFdC, we in-
serted the genes encoding for the human equilibrative nucleoside 
transporter 1 (hENT1) (33) and the human deoxycytidine kinase 
(dCK) (34), both under the control of the constitutive adh promoter, 
into the S. pombe genome. This facilitates the import of dFdC into 
S. pombe cells and the subsequent phosphorylation of dFdC into 
dFdCMP and, subsequently, through two phosphorylation steps by 
endogenous nucleoside monophosphate and nucleoside diphos-
phate kinases (35) into dFdCTP (see Fig. 1A).
As shown in Fig. 1B, strains without hENT1 and dCK, as well as 
cells with only hENT1 but not dCK, were resistant to 1 M dFdC, 
while cells expressing both hENT1 and dCK were sensitive. We 
measured intracellular dNTP and dFdCTP levels, as shown in 
Fig. 1C, treating hENT1 dCK strains with dFdC led to the appear-
ance of dFdCTP, resulting from the triple phosphorylation of 
dFdC. Similar to the effects observed in human cells (22), S. pombe 
dNTP pools were reduced after dFdC treatment in hENT1 dCK 
cells. We could detect dFdCMP, dFdCDP, and dFdCTP in hENT1 
dCK cells treated with dFdC but not in dFdC-treated cells, which do 
not contain hENT1 and dCK (fig. S1). These results show that inser-
tion of the hENT1 transporter and dCK kinase successfully creates a 
nucleotide salvage pathway in S. pombe, which sensitizes cells to dFdC.
MRN and Ctp1 promote resistance to dFdC and removal 
from genomic DNA
To study whether the MRN complex and the S. pombe Sae2/CtIP 
homolog Ctp1 (36) contribute to dFdC resistance, we tested the 
sensitivity of deletion mutants to dFdC and found that these were 
all sensitive (Fig. 2A). Next, to assess whether these mutants were 
deficient in removing dFdC from genomic DNA after incorporation, 
we quantified dFdC in genomic DNA. Briefly (for details, see Mate-
rials and Methods), wild-type (WT) and mutant cells were treated 
for 3 hours with dFdC and a stable “heavy” isotope of deoxycyti-
dine, 15N3dC (hdC). Genomic DNA was isolated and subsequently 
enzymatically digested and dephosphorylated into single nucleosides. 
Using liquid chromatography–tandem mass spectrometry (LC-MS/
MS), the amounts of dFdC and hdC in genomic DNA were quanti-
fied. To correct for differences in replication progression between 
the strains, we calculated the dFdC/hdC ratio, which reflects the 
amount of dFdC in genomic DNA corrected for the total amount of 
replication taken place during dFdC/hdC treatment. As shown in 
Fig. 2B, the dFdC/hdC ratios were significantly increased ~2.5- to 
3-fold in the deletion mutants compared to WT.
Several studies have shown that dFdC is incorporated into ge-
nomic DNA during S phase and that this is responsible for its cyto-
toxic effect, rather than dNTP pool depletion (23, 37, 38). In our 
study, under the treatment conditions used to measure the dFdC/
hdC ratio (50 M dFdC), cells are arrested in early S phase (as 
shown in Fig. 4; cells are arrested when exposed to 2 M dFdC). As 
dFdC is not incorporated outside of S phase and cells do not prog-
ress through S phase at high dFdC concentrations, the increase in 
the dFdC/hdC ratio in the deletion mutants is best explained with a 
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deficiency in removing dFdC from the nascent strand during DNA 
replication, suggesting that dFdC removal is promoted by the MRN 
complex and Ctp1.
Mre11 nuclease activity contributes to dFdC resistance 
and removal
To assess a potential contribution of Mre11 nuclease activity to 
dFdC resistance, we tested the sensitivity of two different mre11 nu-
clease mutants (impaired for both endo- and exonuclease activity), 
mre11-D65N (9, 39) and mre11-H134S (40), to dFdC. As shown in 
Fig. 3A, both nuclease mutants are sensitive to dFdC.
dFdC acts as a chain terminator but also as an inhibitor of RNR, 
thus decreasing dNTP pools. To test whether the sensitivity of 
S. pombe mre11 nuclease dead mutants can be (partially) attributed 
to a potential role in resisting dNTP depletion, we tested mre11-H134S 
and the exonuclease mutant mre11-H68S (see also below) (40) for 
sensitivity against hydroxyurea (HU), another RNR inhibitor. As 
shown in Fig. 3B, these mre11 mutants were not hypersensitive to 
HU at concentrations that substantially sensitize mre11 cells. 
While this confirms that the MRN complex is involved in resisting 
dNTP pool depletion (41), it suggests that this function is not medi-
ated by mre11 nuclease activity and that the sensitivity of the mre11 
nuclease mutants to dFdC is not due to a role of this activity in re-
sisting dNTP depletion but is more likely explained by its dFdC re-
moval defect. We measured the dFdC/hdC ratios and found that 
these are increased in both mre11-D65N and mre11-H134S mutants 
(Fig. 3C), suggesting that the Mre11 nuclease activity removes dFdC 
from genomic DNA during replication.
The increase in genomic dFdC/hdC ratio in mre11 nuclease mu-
tants compared to WT shows that the Mre11 nuclease activity pref-
erentially removes replication-blocking dFdC over hdC (which 
is chemically indistinguishable from dC). We also found that an 
S. pombe deletion of exo1, encoding a nuclease that has been impli-
cated in long-range resection at the replication fork (42), does not 
show an increase in the dFdC/hdC ratio (see fig. S2). This suggests 
that indiscriminate (having no preference for dFdC, hdC, or natural 
deoxynucleotides) long-range resection of stalled forks does not 
affect the dFdC/hdC ratio in our assay. These observations indi-
cate that the increased dFdC/hdC ratio in the mre11 nuclease 
mutants is not due to a role of Mre11 in uncontrolled resection of 
nascent DNA strands at the replication fork.
While the dFdC/hdC ratio in mre11 shows a ~3-fold increase 
compared to WT (Fig. 2B), the increase in the two mre11 nuclease 
mutants is reduced to ~1.5-fold. This might reflect that some dFdC 
is removed by an alternative (MRN-dependent) activity or that the 
mre11 nuclease mutants are only partially nuclease deficient.
Fig. 2. MRN and Ctp1 promote resistance to dFdC and removal from genomic 
DNA. (A) mrn/ctp1 deletion mutants are sensitive to dFdC. Representative exam-
ple of three experiments. (B) The dFdC/hdC ratio is significantly increased in 
mrn/ctp1 deletion mutants compared to WT. Error bars depict SE; asterisk indicates 
statistically significant difference with WT (t test, P < 0.05; n = 3).
Fig. 1. Creation of a nucleotide salvage pathway in S. pombe. (A) Integration of 
the genes encoding for the hENT1 and the dCK into the S. pombe genome. This fa-
cilitates the import of dFdC into S. pombe cells and the subsequent phosphorylation 
of dFdC into dFdCMP and through two subsequent phosphorylation steps into 
dFdCTP. (B) Wild-type (WT) cells without hENT1 and dCK, as well as cells expressing 
only hENT1, are not sensitive to 1 M dFdC; cells expressing both hENT1 and dCK 
are sensitive. (C) Treating hENT1 dCK strains with dFdC led to a reduction in dNTP 
levels, and the appearance of dFdCTP, resulting from the triple phosphorylation of 
dFdC. This shows that dFdC is transformed into dFdCTP in cells containing hENT1 
and dCK. Asterisk indicates a statistically significant difference with untreated cells 
(t test, P < 0.05; n = 3). G, gemcitabine; F, fluorine; P, Phosphate.
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Mre11 nuclease activity supports replication progression 
in the presence of dFdC
Data presented so far suggest that Mre11 nuclease activity contrib-
utes to dFdC resistance by removing chain-terminating dFdC from 
nascent DNA, thus supporting replication progression. We therefore 
assessed replication progression using flow cytometry in synchronized 
WT and mre11-D65N strains. Temperature sensitive nda3-KM311 
cells were arrested at G2-M and, subsequently, released after which 
they performed synchronous mitosis followed by replication (43).
As shown in fig. S3A, after release from the G2 block, the shift to 
G1 (due to mitosis) was barely visible in untreated WT and mre11-
D65N cells. This is because S. pombe cells have a very short G1 phase 
and will initiate DNA replication directly after mitosis, before cyto-
kinesis (see fig. S3B for schematic). When WT and mre11-D65N 
cells were treated with 2 M dFdC, replication was inhibited and 
cells were blocked in early S phase. As shown in Fig. 4A (a different 
representation of the data shown in fig. S3A), in both untreated cells 
and cells treated with 2 M dFdC, there was little difference in repli-
cation progression between WT and mre11-D65N cells. However, in 
cells treated with 150 nM dFdC, we observed delayed S phase pro-
gression in WT and pronounced replication arrest in mre11-D65N cells.
We also compared the replication fork progression between WT 
and mre11-D65N using two-dimensional (2D) gel electrophoresis, 
which allows the analysis of replication intermediates (44). Asyn-
chronous WT and mutant cells were treated with 150 nM dFdC for 
3 hours, after which dFdC was washed out to allow recovery. As 
shown in Fig. 4B, replication intermediates (including Y arc and 
cone signal) accumulated in both strains upon dFdC treatment, 
consistent with a global slowdown in S phase progression. During 
recovery, DNA replication intermediates persisted longer in mre11-
D65N compared to WT, indicating that replication fork progres-
sion was delayed in the absence of Mre11 nuclease activity. Overall, 
the replication intermediates/monomer ratio is significantly higher 
in mre11-D65N compared to WT (P = 0.034, pairwise comparison 
using paired t test). These results show that Mre11 nuclease activity 
supports replication progression after dFdC treatment.
The S. pombe mre11-H68S mutant is mildly sensitive to dFdC
Mre11 has both single-strand endonuclease and 3′ to 5′ exonuclease 
activities. As the polarity of the 3′ to 5′ exonuclease activity is ideal-
ly suited to remove replication blocking nucleoside analogs from 
the growing 3′ end of the nascent DNA strand, we tested whether an 
S. pombe mre11-H68S mutant is sensitive to dFdC. This mutant was 
previously assumed to be defective for the 3′ to 5′ exonuclease ac-
tivity based on the absence of exonuclease activity in an equivalent 
Pyrococcus furiosus mre11 mutant in vitro (40). As shown in Fig. 5A, 
the mre11-H68S mutant was mildly sensitive to dFdC compared to 
WT but less sensitive than the mre11-H134S mutant, which is defi-
cient for both endo- and exonuclease activities. We also determined 
the dFdC/hdC ratio in this mutant and found that it showed a small 
insignificant increase compared to WT (see Fig. 5B). However, it 
was previously shown that the equivalent S. cerevisiae mutant pro-
tein Mre11-H59S showed reduced, but not abolished, 3′ to 5′ 
exonuclease activity in biochemical assays (4). Thus, while the 
slight sensitivity of the mre11-H68S mutant suggests that the 
exonuclease activity contributes to dFdC resistance, the extent of 
this role might be masked by residual exonuclease activity in the 
mre11-H68S mutant.
Mre11 3′ to 5′ exonuclease activity contributes to dFdC 
resistance and removal in DT40 and MRC-5 cells
As results obtained using the S. pombe mre11-H68S mutant were 
not conclusive and to determine whether the role of the Mre11 nu-
clease activity has been conserved in higher eukaryotes, we decided 
to study dFdC resistance and removal in chicken DT40 and human 
MRC-5 cells. First, to assess the contribution of Mre11 nuclease ac-
tivity to dFdC removal and resistance in vertebrate cells, we created 
an MRE11H129N/− nuclease mutant (defective for both endo- and 
exonuclease activity) in DT40 cells, expressing the mutant protein 
from its endogenous promotor, preserving the intron/exon struc-
ture of the gene (see Materials and Methods for details). As shown 
in Fig. 6A (blue lines), this mutant was sensitive to dFdC compared 
to MRE11+/− cells. We also measured genomic dFdC incorporation 
in this mutant and found that the dFdC/hdC ratio (Fig. 6B) in-
creased approximately fourfold in MRE11H129N/− cells compared to 
MRE11+/− cells.
To assess whether the Mre11 3′ to 5′ exonuclease activity, rather 
than the single strand endonuclease activity, contributes to dFdC 
resistance and removal, we tested dFdC sensitivity of both DT40 
MRE11+/− and MRE11H129N/− cells treated with different concentra-
tions of mirin, which has been shown to specifically inhibit the 
Mre11 3′ to 5′ exonuclease but not the endonuclease activity (6, 40). 
Increasing concentrations of mirin (Fig. 6A, green and red lines) 
Fig. 3. Mre11 nuclease activity contributes to dFdC resistance and removal. 
(A) The mre11 nuclease mutants mre11-D65N and mre11-H134S are sensitive to 
dFdC. Representative example of three experiments. (B) mre11 nuclease mutants 
are not sensitive against hydroxyurea (HU) concentrations, which sensitize an 
mre11 deletion mutant. (C) The dFdC/hdC ratio is significantly increased in mre11 
nuclease mutants compared to WT. Error bars depict SE; asterisk indicates statisti-
cally significant difference with WT (t test, P < 0.05; n = 3 for WT and mre11-H134S; 
n = 6 for mre11-D65N).
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Fig. 4. Mre11 nuclease activity supports replication progression in the presence of dFdC. (A) Flow cytometric analysis of WT (blue) and mre11-D65N (red) cells, 
synchronized and released in G2 in the presence of 0, 150 nM, and 2 M dFdC. This is an alternative presentation of data shown in fig. S3, allowing direct comparison 
between WT and mre11-D65N cells. Flow cytometric profiles in the absence of dFdC and in the presence of 2 M dFdC show little difference between WT and mre11-D65N 
cells. In the presence of 150 nM dFdC, WT cells (blue) slowly progress through S phase from 1C to 2C, whereas the great majority of mre11-D65N cells (red) fail to progress 
and display a 1C content throughout the time course. Representative example of three experiments. (B) Quantification of the combined replication intermediates (Y arc 
and cone structures) relative to the (nonreplicating) monomer spot shows that replication intermediates persist in the mre11-D65N mutant, suggesting that Mre11 
nuclease activity is required for recovery from dFdC treatment. Left: Representative example of two experiments. Right: Quantification of replication intermediate 
signal/monomer spot ratio, relative to the ratio in untreated asynchronous cells. Average of two experiments, “x” depicts the values from individual experiments from 
which the average was calculated. The replication intermediates (RI)/monomer ratio is significantly higher in mre11-D65N compared to WT (pairwise comparison using 
paired t test, P = 0.034).
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sensitized MRE11+/− cells to dFdC, whereas MRE11H129N/− 
cells were not sensitized beyond the sensitivity caused by the 
MRE11H129N/− mutation. We obtained similar results using another 
Mre11 exonuclease inhibitor, PFM39 (see fig. S4). After mirin treat-
ment, the dFdC/hdC ratio increased approximately fourfold in 
MRE11+/− cells compared to untreated cells, while mirin treatment 
did not further increase the dFdC/hdC ratio in MRE11H129N/− cells 
(Fig. 6B). The observation that mirin treatment does not increase 
dFdC sensitivity or the dFdC/hdC ratio in MRE11H129N/− cells con-
firms that mirin specifically targets Mre11 (exo)nuclease activity 
and that the effects of mirin on dFdC sensitivity and the dFdC/hdC 
ratio in MRE11+/− cells are not due to interference of mirin with 
other (nuclease) activities.
We also measured the amount of constituent dC in genomic 
DNA for a subset of experiments which formed the basis for 
Fig. 6B. As shown in fig. S5, which depicts the number of genomic 
dFdC and hdC molecules per 104 dC molecules in genomic DNA, 
the increased dFdC/hdC ratio in mirin-treated MRE11+/− cells and 
in MRE11H129N/− cells results from an increase in dFdC accompanied 
by a smaller increase in hdC. This suggests that the Mre11 nuclease 
activity removes (chain-terminating) dFdC together with a stretch 
of newly synthesized DNA.
We also tested the effect of mirin on dFdC sensitivity and the 
dFdC/hdC ratio in human lung fibroblast MRC-5 cells. As shown in 
Fig. 6C, mirin treatment increased the sensitivity of MRC-5 cells to 
dFdC (Fig. 6C, left) and also increased the dFdC/hdC ratio (Fig. 6C, 
right). Last, to assess whether the Mre11 endonuclease activity con-
tributes to dFdC resistance, we treated MRC-5 cells with 60 M 
Mre11 endonuclease inhibitor PFM03 (6) and found that it does 
not increase dFdC sensitivity (Fig. 6D). Our observations suggest 
that the Mre11 3′ to 5′ exonuclease activity, but not the endonuclease 
activity, contributes to dFdC resistance and removal in DT40 and 
MRC-5 cells.
DISCUSSION
Treatment with DNA damaging and replication inhibiting agents is 
one of the mainstays of cancer therapy. While defects in DNA re-
pair pathways associated with carcinogenesis can sensitize cancer 
cells to treatment, it remains largely unknown which (often redun-
dant) repair pathways/activities are responsible for repairing DNA 
damage caused by commonly used cancer drugs. Identification of 
and mechanistic insight into these pathways is important to improve 
treatment efficacy by tailoring the choice of drug to DNA repair 
defects present in cancer cells (personalized medicine) or by exploit-
ing synthetic lethality with novel DNA repair–inhibiting drugs (45).
Artificial chain-terminating nucleoside analogs (e.g., dFdC and 
cytarabine) are extensively used not only in cancer treatment but 
also in antiviral therapy (46). Whereas nucleoside analogs used in 
cancer treatment target the replication machinery in the cancer cell, 
antiviral nucleoside analogs are designed to inhibit viral replication; 
integration into the genomic DNA of the host cell causes unwanted 
side effects (47). Therefore, identification of cellular activities that 
resist treatment with these drugs is also important to understand 
the off-target effects of (novel) antiviral nucleoside analogs.
While recent studies in yeast and human cells have implied a 
role for the Mre11 3′ to 5′ exonuclease activity in DSB end resection 
in meiotic and nonmeiotic cells, its role during replication has re-
mained elusive. The 3′ to 5′ exonuclease activity of recombinant 
yeast Mre11 acts on blunt-ended double-strand DNA or a 3′ DNA 
end with a 5′ overhang but is not active toward a 3′ overhang (19). 
This activity is thus ideally suited to remove nucleotide analogs 
from the nascent 3′ end during replication. In this study, we have 
shown that inhibition of the Mre11 3′ to 5′ exonuclease activity sen-
sitizes cells to dFdC and leads to an increase in dFdC in genomic 
DNA. This suggests that Mre11 exonuclease activity removes dFdC 
from genomic DNA during DNA replication, contributing to the 
innate resistance of cells against this drug.
Most previous studies on replication fork stalling have concen-
trated on stalling caused by nucleotide pool depletion or obstacles 
on the template strand (20). Under treatment conditions used in 
our study to quantify the dFdC/hdC ratio in genomic DNA, cells 
arrest at the first opportunity for dFdC to be integrated into genomic 
DNA, which is S phase. To the best of our knowledge, our study 
is the first to identify an activity that removes a chain-terminating 
nucleoside analog from the nascent (rather than the template) strand 
during DNA replication in vivo.
Our study demonstrates a role for Mre11 nuclease activity in 
dFdC removal in the model eukaryote S. pombe, in chicken DT40 
cells, and in human MRC-5 cells, suggesting that this role in removing 
chain-terminating nucleotides from DNA has been conserved during 
evolution. While cells are unlikely to encounter dFdC in the natural 
environment, some recent studies suggest that chain-terminating 
nucleosides are present within the cellular free nucleoside/nucleotide 
pool, which is prone to endogenous damaging modifications; free 
nucleotides are much more susceptible to modifications than nucle-
otides already incorporated into DNA (48, 49). While the effect of 
integration of naturally occurring noncanonical nucleotides into 
Fig. 5. The S. pombe mre11-H68S mutant is mildly sensitive to dFdC. (A) While 
the mre11-H134S nuclease mutant, which is impaired for both endo- and exonuclease 
activity, is sensitive to 400 nM dFdC, the mre11-H68S mutant is only mildly sensi-
tive. Representative example of three experiments. (B) The dFdC/hdC ratio is sig-
nificantly increased in mre11-D65N and mre11H134S (same data as shown in Fig. 3C 
to allow direct comparison) compared to WT, mre11-H68S shows a small but insig-
nificant increase. Error bars depict SE. Asterisk indicates a statistically significant 
difference with WT (t test, P < 0.05; n = 3 for WT and mre11-H134S, n = 6 for mre11-
D65N, and n = 3 for mre11-H68S).
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genomic DNA is an underresearched area of study, there is evidence 
from biochemical assays with human proteins that incorporation of 
the oxidized nucleotide 8-oxo-dGTP into genomic DNA delays or 
terminates chain elongation (50, 51). It is, thus, possible that the 
Mre11 nuclease activity has evolved to remove noncanonical, endog-
enously damaged chain-terminating nucleotides from DNA during 
replication.
Previous studies have shown involvement of MRE11 exonuclease 
activity in uncontrolled deleterious degradation of DNA at the rep-
lication fork in cells that are deficient for HR (e.g., when RAD51 or 
BRCA2 are mutated/depleted); however, these studies have not re-
vealed a beneficial role of Mre11 exonuclease activity in supporting 
progression of stalled forks in recombination-proficient cells. Our 
observations that the Mre11 exonuclease activity preferentially re-
moves dFdC over hdC (which is chemically indistinguishable from 
dC) and that deletion of exo1 does not lead to an increase in the 
dFdC/hdC ratio show that the Mre11-dependent dFdC removal ac-
tivity we uncovered is not the result of indiscriminate resection and 
is, thus, distinct from the previously described role of Mre11 nucle-
ase activity in the uncontrolled deleterious resection resulting from 
defective HR.
We have thus uncovered a previously unidentified role for the 
Mre11 exonuclease activity in supporting replication fork progression, 
which has major implications for our understanding of the evolu-
tionary conserved role of Mre11 in unblocking stalled replication 
forks. These findings will form a basis for future studies into the role 
of Mre11 and other (nuclease) activities in the removal of naturally 
occurring endogenously damaged nucleosides and artificial nucleo-
side analogs used in cancer and antiviral therapy.
MATERIALS AND METHODS
S. pombe strains and techniques
For strain construction and propagation, standard genetic methods 
and media were used (52). Strains used and constructed in this study 
are listed in table S1. For spot tests, cultures were diluted to 107 cells/ml 
and 10-fold diluted to 102 cells/ml. Of these dilutions, 10 l were 
spotted for each culture on each plate.
The dCK gene (34) under control of the S. pombe adh promoter, 
was integrated into the S. pombe genome, replacing ura4. Subsequently, 
the hENT1 gene (33), under control of the adh promoter, coupled to 
a nourseothricin resistance marker, was integrated adjacent to dCK. 
Strains containing dCK and hENT1 were grown on minimal media 
(Edinburgh Minimal Medium and glutamate), as they display slow 
growth and elongated cell phenotype on yeast extract. For the high- 
performance liquid chromatography (HPLC)–based quantification 
Fig. 6. Mre11 3′ to 5′ exonuclease activity contributes to dFdC resistance and removal in DT40 and MRC-5 cells. (A) MRE11H129N/− DT40 cells are sensitive to dFdC 
compared to MRE11+/− cells in the absence of the exonuclease inhibitor mirin (blue line). In MRE11+/− cells, the addition of mirin (green and red lines) increases dFdC 
sensitivity, whereas in MRE11H129N/− cells, mirin does not sensitize against dFdC beyond the sensitivity caused by the nuclease mutation. Error bars depict SE; n = 3. 
(B) Mirin treatment increases the dFdC/hdC ratio in MRE11+/− cells. MRE11H129N/− cells also show an increased dFdC/hdC ratio, but the addition of mirin to the nuclease 
mutant cells does not further increase the dFdC/hdC ratio. Error bars depict SE. Asterisk indicates statistically significant difference with MRE11+/− cells (t test, P < 0.05; 
n = 7). (C) Mirin treatment increases dFdC sensitivity (left; error bars depict SE; n = 3) and increases the dFdC/hdC ratio in MRC-5 cells (right; error bars depict SE; asterisk 
indicates statistical significance; t test, P < 0.05; n = 7). (D) The Mre11 endonuclease inhibitor PFM03 does not sensitize MRC-5 cells to dFdC. Error bars depict SE; n = 3. 
DMSO, dimethyl sulfoxide.
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of free cellular dNTP and dFdCTP pools, the procedure described in 
(53) was followed.
To assess replication progression using flow cytometry, asyn-
chronous nda3-KM311 cells were arrested in G2 by a 6-hour incu-
bation at restrictive temperature (16°C) and released at permissive 
temperature (30°C) in the presence of dFdC. Samples were taken 
every 30 min and were processed for flow cytometry according to 
the standard procedures (54). 2D gel electrophoresis (in the absence 
of trimethylpsoralen) was performed, as described (42), using the 
AseI/BamHI ura4+ fragment.
For mass spectrometric detection of genomic dFdC and hdC, a 
100-ml S. pombe culture at a density of 4 × 106 cells/ml was treated 
for 3 hours with 50 M dFdC and 50 nM hdC. Cells were harvested 
and genomic DNA was isolated, as previously described (55), with 
minor modifications (detailed protocol available on request).
DT40 and MRC-5 cell lines and techniques
DT40 (56) and MRC-5 (SV40 transformed; provided by A. R. Lehmann, 
University of Sussex) cells were maintained using standard methods 
and media. The DT40 MRE11H129N/− nuclease mutant was created 
from MRE11+/− cells (57) provided by S. Takeda (Faculty of Medicine, 
Kyoto University) by a targeted knock-in, leaving MRE11 under 
control of its own promoter, and apart from the H129N mutation in 
exon 4 and integration of a puromycin resistance marker in the in-
tron downstream of this mutation, leaving the overall intron/exon 
structure intact.
For DT40 colony survival assays, cells were exposed to drugs for 
24 hours in liquid medium, before being plated in methylcellulose- 
containing media (56). For MRC-5 colony survival assays, cells were 
exposed to drugs for 24 hours before being processed (58).
The MTS assay was carried out using a CellTiter 96 AQueous 
One Solution Cell Proliferation Assay kit (Promega). DT40 cells 
(50,000 per well) were incubated for 4 hours at 39°C, after which 
drugs and compounds were applied. Cells were incubated for an 
additional 48 hours at 39°C. MTS reagent (20 l) was added to each 
well, and cells were incubated for 4 hours.
Absorbance was read at 490 nm using a microplate reader and 
corrected for the absorbance of wells containing medium without 
cells or drugs. Rates of metabolic activity were expressed as a per-
centage relative to untreated control cells.
For mass spectrometric detection of genomic dFdC and 13C15NdC, 
5 ml of DT40 (1 × 106 cells/ml) were treated with 500 nM dFdC and 
10 nM 13C15NdC and varying doses of Mirin for 24 hours. MRC-5 
cells were grown to 50% confluence in a 100-mm cell culture dish and 
treated with 10 nM 13C15NdC and 1 M dFdC for 24 hours. Genomic 
DNA was isolated using the QIAGEN DNeasy Blood and Tissue Kit.
Preparation of genomic DNA and nucleoside quantification 
by LC-MS/MS
Genomic DNA obtained from S. pombe, DT40, or MRC-5 cells was 
hydrolyzed and dephosphorylated by a combination of nuclease P1 
(Sigma-Aldrich, N8630), phosphodiesterase I (Sigma-Aldrich, P3243), 
and alkaline phosphatase (Sigma-Aldrich, P5931) into single nucle-
osides, as previously described (59). Nucleosides were separated 
using a C18 reverse-phase HPLC column and quantified by an in-
line triple quadrupole mass spectrometer. The mass/charge ratio 
transitions used for detecting the various nucleosides were as follows: 
dFdC, 264.1 → 112.1; hdC, 231.1 → 115.0; 13C15NdC, 240.1 → 119.1; 
dC, 228.1 →  112.1; deoxyadenosine, 252.1 →  136.1; deoxyguanosine, 
268.1 → 152.1; and thymidine, 243.1 → 127.1. A detailed protocol 
is available on request. Using this methodology, we typically detect ~1 
dFdC per 16,000 dC in WT DT40 cells not treated with mirin; this is well 
above the dFdC detection limit, which we estimate to be ~1 dFdC per 
70,000 dC.
Statistics
Statistical significance was tested using the (paired or unpaired) 
Student’s t test. P < 0.05 was considered to be significant. Analysis 
was based on at least three independent experiments, for details see 
Results and figure legends.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/22/eaaz4126/DC1
View/request a protocol for this paper from Bio-protocol.
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